European Journal of Endocrinology · 2010 · 61 citations · 13 references
MedicineNuclear MedicineOncologyCancer GeneticsMolecular OncologyNeoplasiaMalignant NeoplasmsMolecular Tumor ProfilingThyroid CancerThyroid DisordersThyroid ImagingThyroid Uptake StudiesBraf V600 MutationsBraf V600e MutationPapillary Thyroid Carcinoma ImagingRecurrent Cervical CancerRecurrent Cervical NeoplasiaRecurrent Thyroid Cancer DetectionSerum Tumor MarkersThyroid Tumor Imaging
OBJECTIVE: BRAF V600E is a potential marker of poor prognosis in papillary thyroid cancers (PTC). In a previous report, we showed that recurrent PTC with no radioiodine ((131)I) uptake are frequently associated with BRAF mutations, a low expression of thyroid-related genes and a high expression of glucose type-1 transporter gene. AIM: The aim of the present study was to assess BRAF status in a large series of recurrent PTC patients, considering paired primary and recurrent cancers. The BRAF genotype was correlated with the ability to concentrate (131)I and/or 2-[(18)F]fluoro-2-deoxi-d-glucose ((18)F-FDG) in the recurrent cancers, serum markers of recurrence, and patient outcome. DESIGN AND METHODS: We studied 50 PTC patients with recurrent cervical disease submitted to a re-intervention, followed up in median for 9 years. BRAF analysis was conducted by direct sequencing and mutant allele-specific PCR amplification. In 18 cases, molecular analysis was also assessed in the primary cancer. Out of 50 patients, 30 underwent (18)F-FDG-positron emission tomography-computed tomography. RESULTS: BRAF V600E-positive recurrent patients were found (131)I-negative in 94% of cases (P<0.001); 73% of the cancers carrying BRAF V600E were both (131)I-negative and (18)F-FDG positive. In paired primary and recurrent PTC, BRAF V600E was observed in 79% of the primary cancers and 84% of their recurrences. Three patients with (131)I-negative and BRAF V600E-positive recurrent cancers deceased during follow-up. CONCLUSIONS: BRAF mutations are more common in thyroid recurrences with no (131)I uptake than in (131)I-positive cases. They are correlated with the ability to concentrate (18)F-FDG, and they can appear, albeit rarely, as a de novo event in the course of PTC recurrences.
13
Richard J. Robbins, Qiang Wan, Ravinder K. Grewal et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 585 citations
Medicine, Nuclear Medicine, Oncology +17
Julio C. Ricarte‐Filho, Mabel Ryder, Dhananjay Chitale et al. · Cancer Research · 2009 · 527 citations · Full text
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xiulong Xu, Roderick M. Quiros, Paolo Gattuso et al. · PubMed · 2003 · 423 citations